Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. develops clinical-stage protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Company news centers on the rinvatercept (KER-065) program for neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, as well as elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Recurring updates include clinical data presentations, research collaborations, business highlights, financial results, and licensing economics tied to Takeda. Keros also reports governance changes, corporate presentations, portfolio prioritization, and capital actions such as its completed common-stock tender offer and capital return program.
Keros Therapeutics presented new clinical data from its ongoing Phase 2 trials of elritercept (KER-050) at the 29th Annual Hybrid Congress of the European Hematology Association. The data highlights elritercept's potential in treating lower-risk myelodysplastic syndromes (MDS) and myelofibrosis (MF). Key findings include durable transfusion independence, improved patient fatigue scores, and reductions in spleen volume. Elritercept was generally well-tolerated with no treatment-related fatalities. Keros plans to initiate a Phase 3 clinical trial in MDS following positive FDA feedback, marking a significant step towards potential commercialization.
Keros Therapeutics (Nasdaq: KROS) announced a corporate update conference call and webcast on June 17, 2024, at 8:00 a.m. Eastern time. The company received positive feedback from the FDA regarding its KER-050 (elritercept) program for myelodysplastic syndromes (MDS), aligning on the design and endpoints for the proposed Phase 3 clinical trial. CEO Jasbir S. Seehra, Ph.D., mentioned ongoing Phase 2 TROPOS trial for KER-012 (cibotercept) in pulmonary arterial hypertension (PAH), with enrollment expected to complete in Q4 this year. The webcast will be accessible via Keros’s website, with an archived version available for 90 days post-call.
Keros Therapeutics, a clinical-stage biopharmaceutical company, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference.
The event will be held on June 10, 2024, at 2:40 p.m. Eastern time. Keros' President and CEO, Jasbir S. Seehra, Ph.D., will present at a fireside chat session.
A live audio webcast of the presentation will be available, with an archived replay accessible on the Keros website for 90 days post-event.
Keros Therapeutics, a clinical-stage biopharmaceutical company, appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024.
Bienaimé brings extensive experience from his tenure as CEO and Chairman of BioMarin Pharmaceutical, Genencor, and Sangstat Medical He also held senior positions at Rhône-Poulenc Rorer Pharmaceuticals and Genentech.
Keros' CEO, Jasbir Seehra, emphasized Bienaimé's expertise in executive leadership, strategic planning, and product development, noting it will support Keros' growth and pipeline progression.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that five abstracts from its KER-050 (elritercept) program will be presented at the 29th Annual Congress of the European Hematology Association (EHA) from June 13-16, 2024. These presentations, both virtual and in-person, include findings from an ongoing Phase 2 trial in participants with lower-risk MDS, potential cardiovascular benefits, and KER-050's capacity to treat myelofibrosis and mitigate ruxolitinib-associated cytopenias. Additionally, data shows reduced ferritin levels and increased bone-specific alkaline phosphatase in lower-risk MDS participants, suggesting potential to rebalance the osteohematopoietic niche. A preclinical study demonstrated that KER-050 increased muscle mass and strength in a mouse model of myelofibrosis.
Keros Therapeutics, a clinical-stage biopharmaceutical company, reported a business update and financial results for Q1 2024. The company is focused on developing therapeutics for patients with disorders related to TGF-ß proteins. Key highlights include progress in clinical trials and upcoming milestones for 2024. Financially, Keros reported a net loss of $43.1 million for Q1 2024, attributed to increased research and development expenses. However, the company's cash reserves of $442.4 million as of March 31, 2024, are expected to fund operations until 2027.
Summary not available.
Summary not available.
Summary not available.
Summary not available.